Healio

Adjuvant giredestrant improves invasive DFS in early breast cancer subset

Adjuvant giredestrant significantly improved invasive DFS vs. standard-of-care endocrine therapy in patients with early-stage ...
pharmaphorum

AstraZeneca’s first direct-to-patient program – one year on

pharmaphorum speaks with Steven Davis of AstraZeneca on how the first year of its first direct-to-patient program - ARIMIDEX Direct has been. A year ago, AstraZeneca announced its first ...

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...
pharmaphorum

Generic breast cancer drug cleared for prevention in England

Almost 30 years after it was first licensed as a treatment for breast cancer, aromatase inhibitor anastrozole has been cleared for preventive use in women at high risk of developing the disease in ...